Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Sanofi ends...

    Sanofi ends development of Clostridium difficile vaccine

    Written by Ruby Khatun Khatun Published On 2017-12-05T09:45:04+05:30  |  Updated On 5 Dec 2017 9:45 AM IST
    Sanofi ends development of Clostridium difficile vaccine

    Pharmaceutical company Sanofi SA said on Friday that it had ended development of an experimental vaccine for Clostridium difficile infection after an early look at late-stage trial results indicated a low probability of success.


    About three million Americans have infected annually with the bacterium - also known as C. diff - which spreads mainly through hospitals, nursing homes, and doctors’ offices.


    The move marks the second blow in a week to Sanofi’s vaccine program after the Paris-based company on Wednesday said the use of its new dengue vaccine will be strictly limited due to evidence it can worsen the disease in people who have not previously been exposed to the mosquito-borne virus.


    Sanofi’s Dengvaxia vaccine is the world’s first approved shot for preventing dengue infection, which kills about 20,000 people a year and infects hundreds of millions.


    The company said in a statement that all data from vaccinated volunteers in the C. diff trial will continue to be analyzed for more information and shared with the scientific community.


    As many as 30,000 Americans die each year from the bacterium, usually after recurrences of infection. The infections are typically the result of taking antibiotics, which wipe out friendly bacteria in the colon that normally keep C. diff under control.


    Sanofi said it will continue to focus on six other vaccine projects in development.




    (Reporting by Deena Beasley; editing by Rosalba O'Brien and G Crosse)



    Clostridium difficileDengue vaccineDengvaxiadevelopmentdoctorendshospitalsinfectionlow probabilitymosquito borne virusnursing homespharma newsSanofisuccessvaccine
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok